医生表示，阿司匹林或许能够有助对抗侵袭性乳腺癌，让那些很难治疗的肿瘤对某些抗癌药物产生更积极的反应。

Around one in five breast cancers are triple-negative. It’s a type that hormone treatment and most targeted cancer drugs don’t work against. 

大约五分之一的乳癌病例属于三阴性乳腺癌。激素治疗和大部分针对性抗癌药物对这种乳腺癌都没有作用。

8,000 women are diagnosed with this type of breast cancer every year and it disproportionately affects those aged under 40 and black. They face a treatment combination of surgery, chemotherapy and radiotherapy that can come with side effects.

每年有八千名女性被诊断患上三阴性乳腺癌，而且影响到40岁以下人群和黑人族群的比例很大。这些患者接受综合治疗，包括外科手术、化学疗法和放射疗法，但这些治疗方法可能会引起副作用。

If the clinical trial in humans using aspirin is successful, it could boost the effectiveness of the immunotherapy drug avelumab, which helps the immune system target and attack cancer. Trials on animals have been successful.

如果在人体使用阿司匹林的临床试验取得成功，将可以提高免疫疗法药物 avelumab 的有效性，这种药物帮助免疫系统针对性地攻击癌症。目前，在动物身上的试验已经获得成功。

Dr Anne Armstrong, the trial lead, says that inexpensive aspirin, combined with immunotherapy, could ultimately provide a safe new way to treat breast cancer.

领导试验的安妮·阿姆斯特朗博士指出，使用价格低廉的阿司匹林和免疫疗法相结合，或许最终可以为对抗乳腺癌提供新的安全治疗方法。

词汇表

targeted 针对性的
disproportionately 不成比例地
chemotherapy 化学疗法
radiotherapy 放射疗法
immunotherapy 免疫疗法
inexpensive 便宜的，价格低廉的

阅读理解：请在读完上文后，回答下列问题。

1. What proportion of cases of breast cancer are triple-negative?

2. Which demographic is most affected by triple-negative breast cancer?

3. What treatment do people who have triple-negative breast cancer usually receive?

4. Which drug’s effectiveness could be boosted by aspirin?

答案  

1. What proportion of cases of breast cancer are triple-negative?
Around one in five.

2. Which demographic is most affected by triple-negative breast cancer?
People who are under 40 and those who are black.

3. What treatment do people who have triple-negative breast cancer usually receive?
They face a treatment combination of surgery, chemotherapy and radiotherapy that can come with side effects.

4. Which drug’s effectiveness could be boosted by aspirin?
Aspirin could boost the effectiveness of the immunotherapy drug avelumab.